These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17365170)

  • 41. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
    Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
    J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression.
    Moirand R; Galvao F; Dondé C
    J Clin Psychopharmacol; 2019; 39(6):684-685. PubMed ID: 31688405
    [No Abstract]   [Full Text] [Related]  

  • 43. First depression patch approved.
    FDA Consum; 2006; 40(3):4. PubMed ID: 16909484
    [No Abstract]   [Full Text] [Related]  

  • 44. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.
    Ashton AK
    Ann Clin Psychiatry; 2009; 21(1):51-2. PubMed ID: 19239833
    [No Abstract]   [Full Text] [Related]  

  • 46. Critical appraisal of selegiline transdermal system for major depressive disorder.
    Cristancho MA; Thase ME
    Expert Opin Drug Deliv; 2016; 13(5):659-65. PubMed ID: 26837935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MAOIs and depression treatment guidelines.
    Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):e24. PubMed ID: 22901357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacotherapy for late-life depression.
    Alexopoulos GS
    J Clin Psychiatry; 2011 Jan; 72(1):e04. PubMed ID: 21272511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoamine oxidase inhibitors--current status.
    Zemishlany Z; Radwan M; Wijsenbeek H
    Isr J Psychiatry Relat Sci; 1983; 20(3):254-71. PubMed ID: 6325369
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revisiting monoamine oxidase inhibitors.
    Krishnan KR
    J Clin Psychiatry; 2007; 68 Suppl 8():35-41. PubMed ID: 17640156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Goldberg JF; Portland KB
    J Affect Disord; 2013 Nov; 151(2):409-417. PubMed ID: 23890583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
    Pare CM; Al Mousawi M; Sandler M; Glover V
    J Affect Disord; 1985 Sep; 9(2):137-41. PubMed ID: 2932486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 58. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.
    Cooper AJ
    Br J Psychiatry Suppl; 1989 Oct; (6):38-45. PubMed ID: 2695126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STAR*D: a summary and UK perspective.
    Deakin J; O'Loughlin C
    J Psychopharmacol; 2009 Aug; 23(6):605-12. PubMed ID: 19395428
    [No Abstract]   [Full Text] [Related]  

  • 60. The modern pharmacopoeia: a return to depressive realism?
    Goldberg JF
    Bipolar Disord; 2008 Dec; 10(8):969-72. PubMed ID: 19594511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.